ReNeuron Group plc
("ReNeuron" or the "Company")
Notice of Results
Investor presentation
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, will announce its preliminary results for the year ended 31 March 2023 on Thursday 25 May 2023.
Investor Briefing
Management will also be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 9:30am BST on Thursday 25 May 2023. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/reneuron-group-plc/register-investor
Investors who already follow ReNeuron on the Investor Meet Company platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.
ENDS
Enquiries:
| ReNeuron | |
| Iain Ross, Executive Chairman | Via Walbrook PR |
| John Hawkins, Chief Financial Officer | |
|
|
|
| Allenby Capital Limited (Nominated Adviser and Broker) | +44 (0)20 3328 5656 |
| James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance) |
|
| Stefano Aquilino (Sales & Corporate Broking) |
|
|
|
|
| Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 |
| Paul McManus / Alice Woodings | |
| | +44 (0)7980 541 893 / +44 (0)7407 804 654 |
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.